Rubicon Research Share Price Today | Stock Price & Rubicon Research Share Screener
As of November 19, 2026, the live Rubicon Research share price (NSE: RUBICON) is ₹1,722.30 on NSE and ₹1,726.00 on BSE, up 3.86% from the previous close, with shares trading between ₹1,650.80 and ₹1,745.10 in today's trading session, and a 52-week range of ₹615.20–₹1,860.60. Track Rubicon Research marketcap in USD to gauge the company's total market size. Use the Rubicon Research stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Rubicon Research opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Over the trailing twelve months the company reported revenue of ₹579 and net income of ₹90, with EBITDA of ₹146, an operating margin of 25.0% and a profit margin of 15.5%.
Rubicon Research Share Price Chart
Track the current stock price of Rubicon Research with an interactive chart. Analyse RUBICON share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Rubicon Research stock quote in one place.
The quote of ₹1,722.30 sits between the 52-week low of ₹615.20 and the 52-week high of ₹1,860.60, and the latest session moved 3.86% from the previous close.
Rubicon Research Company Profile - Fundamental Screener
Screen Rubicon Research company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for RUBICON shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Pharmaceuticals & Biotechnology industry, and it trades under ISIN INE506V01022.
Company Details
Classification
Identifiers and Leadership
Rubicon Research Balance Sheet Screener
Screen RUBICON balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹2,327, up from ₹1,451 in 2025.
Latest statistics put total assets at ₹2,327 and shareholder funds at ₹1,289, with a leverage ratio of 0.40.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
Assets |
|||||||
| Total Assets | 2,327 | 1,451 | 1,110 | 750 | 560 | 538 | 430 |
| Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fixed Assets | 532 | 327 | 307 | 199 | 193 | 188 | 157 |
Liabilities |
|||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 202 | 124 | 152 | 102 | 71 | 53 | 12 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
|||||||
| Total Equity | 1,289 | 541 | 385 | 286 | 305 | 374 | 341 |
| Share Capital | 17 | 15 | 15 | 5 | 5 | 5 | 5 |
| Reserves & Surplus | 1,272 | 526 | 370 | 281 | 300 | 369 | 335 |
Rubicon Research Income Statement Screener - Profit & Revenue Analysis
Screen Rubicon Research income statement and profit fundamentals. Analyze RUBICON quarterly results. Rubicon Research reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For 2026-Sept, revenue was ₹579 and net profit was ₹90, equal to earnings per unit of ₹5.47, at an operating margin of 25%.
In that period expenses were ₹432, interest cost ₹11 and tax ₹27. The next period listed, 2026-Jun, shows revenue of ₹540 and net profit of ₹85.
| Item | 2026-Sept | 2026-Jun | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun |
|---|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | ||||||||||
| Revenue | 579 | 540 | 517 | 479 | 413 | 353 | 358 | 314 | 299 | 317 |
| Expenses | 432 | 405 | 395 | 367 | 318 | 273 | 286 | 244 | 234 | 257 |
Operating Costs and Margins | ||||||||||
| EBITDA | 146 | 135 | 121 | 112 | 95 | 80 | 73 | 70 | 64 | 61 |
| Operating Profit % | 25.00% | 24.00% | 23.00% | 23.00% | 23.00% | 22.00% | 20.00% | 22.00% | 21.00% | 19.00% |
| Depreciation | 18 | 15 | 12 | 12 | 12 | 10 | 10 | 9 | 8 | 9 |
| Interest | 11 | 9 | 10 | 10 | 11 | 11 | 12 | 8 | 7 | 10 |
Profit and Earnings | ||||||||||
| Profit Before Tax | 117 | 110 | 99 | 91 | 72 | 60 | 51 | 53 | 49 | 41 |
| Tax | 27 | 26 | 22 | 18 | 18 | 16 | 15 | 15 | 15 | 16 |
| Net Profit | 90 | 85 | 77 | 73 | 54 | 43 | 36 | 38 | 35 | 26 |
| EPS | 5.47 | 5.13 | 4.68 | 4.46 | 3.49 | 2.81 | 2.37 | 2.50 | 2.27 | 1.66 |
Rubicon Research Cash Flow Screener - Liquidity Fundamentals
Screen RUBICON cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2026-March, operating activities generated ₹205, and net cash flow was an inflow of ₹81.
Over the same period, investing activities used ₹407 and financing activities provided ₹283.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March |
|---|---|---|---|---|---|---|---|
Cash from Operations and Investing | |||||||
| Operating Activities | 205 | 159 | 21 | -75 | -63 | 62 | 6 |
| Investing Activities | -407 | -65 | -68 | -32 | -46 | -46 | -84 |
Financing and Net Cash | |||||||
| Financing Activities | 283 | -40 | 44 | 123 | 63 | 52 | 80 |
| Net Cash Flow | 81 | 54 | -4 | 16 | -46 | 67 | 1 |
Rubicon Research Shareholding Pattern Screener
See Rubicon Research shareholding pattern with promoter, FII, and DII holdings. Check Rubicon Research promoter holding and ownership changes for RUBICON on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Mar, promoters held 59.86%, foreign institutions 7.54%, domestic institutions 10.02% and the public 2.82%, spread across 33,738 shareholders.
The shareholder count was 33,738 in 2026-Mar, compared with 43,254 in 2026-Jun.
| Item | 2026-Mar | 2026-Jun | 2026-Sept | 2025-Sept | 2025-Oct | 2025-Dec | 2024-Jul |
|---|---|---|---|---|---|---|---|
Promoter Holding | |||||||
| Promoter Holding | 59.86% | 59.76% | 51.25% | 59.99% | 59.99% | 59.99% | 84.15% |
Institutional Investors | |||||||
| FII Holding | 7.54% | 7.52% | 9.01% | 9.37% | 9.37% | 7.99% | 0.00% |
| DII Holding | 10.02% | 9.43% | 15.72% | 10.54% | 10.54% | 9.45% | 0.00% |
Government, Public and Others | |||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 2.82% | 3.46% | 3.89% | 18.28% | 18.28% | 2.71% | 0.00% |
| Other Holding | 19.76% | 19.84% | 20.13% | 1.82% | 1.82% | 19.86% | 15.85% |
| Shareholder Count | 33,738 | 43,254 | 38,018 | 105,311 | 105,311 | 31,914 | 15 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Rubicon Research. Rubicon Research dividend yield can be compared with peers and other stocks in the market.
The latest dividend recorded was ₹1.50 per unit for 2026-March, a yield of 0.09%, compared with ₹0.02 for 2025-March.
Dividends are listed for 10 periods, with the three most recent payouts at ₹1.50, ₹0.02 and ₹0.00 per unit.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹1.50 | 0.09% |
| 2025-March | ₹0.02 | 0.00% |
| 2024-March | ₹0.00 | 0.00% |
| 2023-March | ₹0.00 | 0.00% |
| 2022-March | ₹0.00 | 0.00% |
| 2021-March | ₹0.00 | 0.00% |
| 2020-March | ₹0.00 | 0.00% |
| 2019-March | ₹0.00 | 0.00% |
| 2018-March | ₹0.00 | 0.00% |
| 2017-March | ₹0.00 | 0.00% |
Rubicon Research Stock Index Membership - Nifty & Sensex
See which indices include Rubicon Research stock. Check RUBICON index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
Complete Index List
Rubicon Research Market Events Screener - Corporate Actions
Get Rubicon Research corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Rubicon Research stock events that may affect RUBICON share price, along with derivatives, futures and options activity and sector gainers.
7 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated November 5, 2026, with a record date of November 5, 2026.
It is followed by Annual General Meeting dated August 26, 2026 and Quarterly Result Announcement dated August 14, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-11-05 | 2026-11-05 | Quarterly Result Announcement | NA | 14.84% |
| 2026-08-26 | 2026-08-26 | Annual General Meeting | NA | 18.65% |
| 2026-08-14 | 2026-08-14 | Quarterly Result Announcement | NA | 5.72% |
| 2026-08-07 | 2026-08-07 | Dividend | ₹ 1.50 /share | 58.39% |
| 2026-05-29 | 2026-05-29 | Quarterly Result Announcement | NA | -0.12% |
| 2026-02-03 | 2026-02-03 | Quarterly Result Announcement | NA | 5.98% |
| 2025-11-13 | 2025-11-13 | Quarterly Result Announcement | NA | -1.76% |
Rubicon Research Competitors Screener - Peer Stocks Comparison
Screen RUBICON competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 448,676 | 40.80 | 61,674 | 12.69% | 11,565 | 60.46 |
| Divis Laboratories | 295,997 | 87.70 | 11,067 | 13.95% | 2,568 | 68.76 |
| Torrent Pharmaceuticals | 177,586 | 85.00 | 13,886 | 20.34% | 2,138 | 47.23 |
| Laurus Labs | 126,325 | 89.90 | 6,868 | 22.01% | 890 | 57.04 |
| Zydus Life Science | 120,119 | 27.60 | 27,658 | 17.64% | 5,026 | 55.91 |
| Dr Reddys Laboratories | 115,854 | 41.80 | 35,059 | 3.90% | 4,158 | 71.26 |
| Cipla | 112,131 | 39.50 | 29,045 | 2.24% | 3,870 | 53.06 |
| Mankind Pharma | 107,805 | 47.90 | 14,636 | 14.85% | 1,938 | 61.37 |
| Aurobindo Pharma | 103,229 | 25.80 | 34,145 | 5.56% | 3,503 | 60.39 |
| Lupin | 89,172 | 17.30 | 29,039 | 26.75% | 5,356 | 39.39 |
Rubicon Research Company Announcements - News & Reports Screener
Screen RUBICON latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated November 17, 2026.
The next most recent announcements are dated November 15, 2026 and November 6, 2026.
| Date | Update | Actions |
|---|---|---|
| 2026-11-17 | Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (SEBI Listing Regulations) W.R.T Update On The Scheme Of Merger Between Rubicon Research Ltd And KIA Health Tech Pvt Ltd. | - |
| 2026-11-15 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | - |
| 2026-11-06 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-11-05 | Audio Recording Of Earnings Conference Call For Thequarter Ended 30Th September 2026. | - |
| 2026-11-05 | Announcement under Regulation 30 (LODR)-Monitoring Agency Report | - |
| 2026-11-05 | Announcement under Regulation 30 (LODR)-Monitoring Agency Report | - |
| 2026-11-05 | Announcement under Regulation 30 (LODR)-Investor Presentation | - |
| 2026-11-05 | Board Meeting Outcome for Outcome Of The Board Meeting Held On November 5 2026 | - |
| 2026-11-05 | Grant Of Stock Options Under Rubicon Research Limited Stock Option Plan 2026 | - |
| 2026-10-30 | Outcome Of USFDA Inspection Of Rubicon Research Ltd Manufacturing Facility In Ambernath India. | - |
| 2026-10-28 | Intimation Regarding Q2 Earnings Conference Call. | - |
| 2026-10-27 | Board Meeting Intimation for Q 2 Ended September 2026. | - |
| 2026-10-09 | Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 -US FDA Inspection Of The Companys Manufacturing Facility In Satara Maharashtra India. | - |
| 2026-10-09 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-10-08 | Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS | - |
| 2026-09-28 | Closure of Trading Window | - |
| 2026-08-29 | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 | - |
| 2026-08-27 | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 | - |
| 2026-08-26 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | - |
| 2026-08-26 | Shareholder Meeting / Postal Ballot-Outcome of AGM | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹1,722.30, within a 52-week range of ₹615.20 to ₹1,860.60. The P/E ratio is 85.20 and the P/B ratio is 19.54, with earnings per unit of ₹15.52. Market capitalisation stands at ₹27,873.92 Cr and the dividend yield is 0.09%. The company operates in the Healthcare sector, in the Pharmaceuticals & Biotechnology industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the NSE and the BSE. Key statistics were last updated on November 20, 2026. This page covers 7 balance sheet periods, 10 income statement periods, 7 cash flow years and 7 shareholding periods. Information is provided for research and is not investment advice.